Anavex Life Sciences Corp (AVXL)

[XenaLives]

Nice find, this couldn't possibly be a report instigated by MJF's advance team, could it?

Follow the report link and there is a statement "Customized multi-client reports being one of our unique selling points, do not hesitate to come up with your precise interests in substantially comprehensive way."


I have no doubt that MJFF will step up to take credit for the research it funded to enable 2-73 to get to P2 in Parkinsons. I won't be surprised if there is additional funding involved, they will not go invisible when Anavex is moving towards possible approval for 2-73.

Health & Wellness
Parkinson’s Disease Therapeutics Market: Promising Pipeline Drugs To Boost The Market Growth

May 23, 2018 Hiren Samani

Parkinson’s disease is an intensifying neurodegenerative disorder that has an effect on the dopamine-generating nerve cells in the brain. It mainly causes muscle stiffness, tremors, gait & balance issues, and improper motor movements. Secondary signs of Parkinson’s disease consist of depression, dementia, and anxiety. The precise reason for Parkinson’s disease is not recognized; it mainly affects the elder people who are over 50 years.

Download Research Report Brochure @ https://www.zionmarketresearch.com/requestbrochure/parkinsons-disease-therapeutics-market

The worldwide Parkinson’s disease therapeutics market is mounting with high occurrence and increase in incidences of the disease around the world. The market is observing a comparatively high growth on account of the increasing wakefulness pertaining to Parkinson’s disease, speedily rising elderly population, new product launches, and promising pipeline drugs.

Furthermore, high clinical research and development funds by the non-profit organizations and governments are also anticipated to propel the expansion of the Parkinson’s therapeutics market in the years to come. The promising product pipeline is a symbol of the potential business development avenues during the coming years.

On the contrary, patent expiration of major branded drugs and the side-effects linked to therapeutic drugs are projected to restrict the development of the Parkinson’s disease therapeutics market in the near future.

Request Free Sample Report @ https://www.zionmarketresearch.com/sample/parkinsons-disease-therapeutics-market

So far, there is no everlasting remedy accessible to treat Parkinson’s disease. Nevertheless, the drugs such as dopamine agonists, levodopa combination therapy, COMT inhibitors, MAO-B inhibitors, amantadine drugs, and cholinesterase inhibitors are being utilized to treat the diverse symptoms linked to the disorder. Levodopa combination therapy is greatly recommended and extensively utilized to treat the motor signs of the Parkinson’s disease.

Recently, an investigational therapy, Anavex 2-73, being assessed in clinical trials for Alzheimer’s disease, was discovered to reinstate the function of injured nerve cells in mouse models of the Parkinson’s disease. Thus, the rise is the development of such drugs is likely to boost the growth of the Parkinson’s disease therapeutics market in the near future.

http://zmrblog.com/2017/3209/parkinsons-disease-therapeutics-market-promising-pipeline-drugs-to-boost-the-market-growth/